Singapore, 12 December 2025 – Esco Aster, a vertically integrated cell and derivatives CRDMO based at JTC LaunchPad Singapore, announced CMC manufacturing support for Shine-On Biomedical’s HLA-G targeted exosome program. Shine-On Biomedical sponsored Esco Aster in 2023 for cGMP services, starting with high-yield exosome development using Esco Aster’s cell line platform. The technical reports of process, analytical, and formulation development, exosome drug loading, GMP engineering runs, and stability studies supported Shine-On’s IND submission. The IND was cleared by the U.S. FDA in Q1 2025. [Read more…]
Stem Cell News
BioInformant's coverage of stem cell news includes iPS cells, mesenchymal stem cells, hematopoietic stem cells, neural stem cells and more.
As the first and only market research firm to specialize in stem cell news, BioInformant research has been cited by the Wall Street Journal, Xconomy, AABB, and Vogue Magazine.
Serving Fortune 500 leaders that include GE Healthcare, Pfizer, and Goldman Sachs, BioInformant is your global leader in stem cell industry news.
What is Lab-Grown Meat and Why Does It Matter?
The potential of lab-grown meat has captured the imagination of investors, researchers, and consumers alike. In the late 1990s, Willem van Eelen was the first applicant to file the first patent for a cultured meat manufacturing method. Although the lab-grown meat industry has only existed for about 25 years, 2020 was a turning point because a cultured chicken product developed by the company “Eat Just” made its debut on a restaurant menu in Singapore. [Read more…]
Applied StemCell Demonstrates Efficient Knock-In of a 50 kb DNA Construct into Human iPSCs Using TARGATT™ Technology
MILPITAS, Calif., Nov. 11, 2025 – Applied StemCell, Inc. (ASC), today announced the successful knock-in of a 50 kilobase (kb) multifunctional DNA insert into human induced pluripotent stem cells (iPSCs) using its proprietary TARGATT™ technology. The achievement establishes a new benchmark for the size and complexity of genetic payloads that can be efficiently and site-specifically integrated into the human genome. [Read more…]
Vector BioMed Expands LENTIVERSE™ Platform and Unveils New Brand Identity to Close the Gap Between CGT Innovation and Patient Access
The expansion of LENTIVERSE™ platform introduces “One Lentiviral Vector Platform, Two Paths to Advance Cures,” aligning scientific rigor with transparent economics and global accessibility.
GAITHERSBURG, Md., Nov. 6, 2025 — Vector BioMed, a leading lentiviral vector supplier and contract vector development and manufacturing organization (CVDMO), today announced the expansion of its LENTIVERSE™ platform alongside the unveiling of its new brand identity, designed to accelerate global gene therapy access by providing custom and ready-to-deploy solutions. This expansion strengthens the company’s mission to make gene therapies more accessible and cost-effective for patients worldwide. [Read more…]
RoosterBio and Secretome Therapeutics Announce Successful Completion of Large Scale Bioreactor Production for Clinical Stage Cell Therapy Candidate STM-01
FREDERICK, Md. and PLANO, Texas, Oct. 6, 2025 — RoosterBio Inc., a leading supplier of human mesenchymal stem/stromal cells (MSCs), highly engineered media, and bioprocess development services, and Secretome Therapeutics, a clinic-stage company developing novel therapies derived from neonatal cardiac progenitor cells (nCPC), today announced completion of commercial scale production of Secretome’s lead nCPC, STM-01. [Read more…]
- « Previous Page
- 1
- …
- 8
- 9
- 10
- 11
- 12
- …
- 145
- Next Page »